2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction
- Author:
Hyun Kuk KIM
1
;
Youngkeun AHN
;
Kiyuk CHANG
;
Young-Hoon JEONG
;
Joo-Yong HAHN
;
Eun Ho CHOO
;
Min Chul KIM
;
Hyo-Soo KIM
;
Weon KIM
;
Myeong-Chan CHO
;
Yangsoo JANG
;
Chong Jin KIM
;
Myung Ho JEONG
;
Shung Chull CHAE
;
Author Information
- Publication Type:Review Article
- From:Korean Circulation Journal 2020;50(10):845-866
- CountryRepublic of Korea
- Language:English
- Abstract: Clinical practice guidelines published by the European Society of Cardiology and the American College of Cardiology/American Heart Association summarize the available evidence and provide recommendations for health professionals to enable appropriate clinical decisions and improve clinical outcomes for patients with acute myocardial infarction (AMI). However, most current guidelines are based on studies in non-Asian populations in the pre-percutaneous coronary intervention (PCI) era. The Korea Acute Myocardial Infarction Registry is the first nationwide registry to document many aspects of AMI from baseline characteristics to treatment strategies. There are well-organized ongoing and published randomized control trials especially for antiplatelet therapy among Korean patients with AMI. Here, members of the Task Force of the Korean Society of Myocardial Infarction review recent published studies during the current PCI era, and have summarized the expert consensus for the pharmacotherapy of AMI.
